Tag: Healthcare & Pharm

SinoMab Announces IND Application of SM17 for the Treatment of Asthma was Accepted by NMPA CDE

HONG KONG, May 22, 2023 – (ACN Newswire) – A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases – SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company"), is pleased to announce that an Investigational New Drug ("IND") application for SM17 (a humanised anti-IL-17RB monoclonal antibody for injection) for the treatment of Asthma has been filed with and accepted by the Center for Drug Evaluation ("CDE") of the National Medical Products Administration of China ("NMPA") on 19 May. The present IND submission, once granted, will enable the Company to conduct comprehensive clinical development program in China which leads to indication for treatment of asthma.

SM17 is a humanized, IgG4-k monoclonal antibody targeting IL-17RB, which is a global first-in-class monoclonal antibody drug targeting IL17BR with the potential for treating asthma, atopic dermatitis, idiopathic pulmonary fibrosis and other immunological disorders. This IND application is mainly for the treatment of asthma, and upon approval of the present IND, the Company plans to initiate a Phase I clinical study in China to bridge between Chinese(Asian) and American(Caucasian/Black) populations, as well as to investigate the safety profile of SM17 in Chinese population.

As early as March 2022, SM17's IND Application for the treatment of asthma was approved by the U.S. Food and Drug Administration ("FDA"), and the first healthy subject had been successfully dosed in a Phase I clinical First-in-Human(FIH) clinical trial in June 2022. As of today, none of the subjects reported a serious adverse event. We are in full steam ahead to accelerate the progress of our clinical study. According to our current progress, we expect the Phase I clinical study can be completed by the end of this year, six months ahead of the original anticipated completion date.

SM17 could suppress Th2 immune responses by binding to IL-17RB on Type 2 Innate Lymphoid cells (ILC2s), blocking a cascade of responses induced by interleukin-25 (IL-25). IL-25 is a critical cytokine classified as "alarmin", which has shown to be implicated in the pathogenesis of airway viral responses and allergic disease, such as asthma. Patients with severe, uncontrolled asthma are at a risk of recurrent asthma exacerbations and hospitalizations, and uncontrolled severe asthma is associated with increased mortality/morbidity, diminished quality of life and increased health expenditures.

As one of the global pandemic, asthma has huge urgent and unmet medical needs, and the pharmaceutical market has a broad space. According to the Frost & Sullivan Report, the number of asthma patients worldwide is gradually increasing and expected to reach 800 million in 2024 and further increase to approximately 860 million in 2030. The number of asthma patients in China grew faster than the global growth rate and is expected to reach 70.4 million in 2024 and further increase to 78.1 million in 2030. In terms of market size, the global asthma product market is expected to reach US $38.5 billion in 2024 and US $50 billion by 2030. The asthma product market in China is expected to reach US $5.6 billion by 2024 and US $9.7 billion by 2030, of which the market size of moderate-to-severe asthma applicable for biologics will reach US $6.6 billion. Current approved therapies for severe asthma, including biologics, can reduce asthma annual exacerbations to a certain extent. However, there is still an unmet medical need for additional effective therapies, particularly for patients who do not respond to current treatments. The Company expected that targeting upstream mediators of the Th2 inflammatory cascade, such as IL-17RB, will have a broad effect on airway inflammation and improve disease conditions. The Company believes SM17 may have great potential to satisfy unmet medical needs in asthma treatment.

Dr. Shui On LEUNG, Executive Director, Chairman and Chief Executive Officer of SinoMab said that, "The number of asthma patients worldwide has increased year by year, and the existing therapies have not fully met the medical needs, and there is still a huge gap in effective treatment of severe asthma. As the world's first humanized IgG4-k monoclonal antibody targeting IL-17RB, SM17 has made satisfactory progress in clinical research under the active promotion of the Company. The acceptance of IND Application for SM17 not only accelerated the Company's clinical development project for the treatment of asthma indications in China, but also demonstrated the high efficiency of our new drug development. The Company is confident in the prospects of clinical trial and commercial development of the new drug of SM17, and will continue to explore its safety and efficacy. It is expected that this new treatment option will benefit more Chinese patients in the future and bring a promising treatment for severe asthma patients. The Company will adhere to independent innovation, continue to promote the investigatory of new drugs, expand the population of indications, spare no effort to provide more effective treatment options for Chinese and global patients, aiming to become a global leader in innovative therapies for immunological diseases."

About SinoMab BioScience Limited
SinoMab BioScience Limited is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The R&D headquarters is located in Hong Kong and the production base is located in mainland China. The Company's flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA) and has completed the Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), Alzheimer's disease, systemic lupus erythematosus (SLE), pemphigus (PV), multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), non-Hodgkin's lymphoma (NHL), asthma, and other diseases with major unmet clinical needs.

This press release is issued by Financial PR (HK) Limited on behalf of SinoMab BioScience Limited. For further information, please contact:

Financial PR (HK) Limited
Contact: Ms. Chloe Chiu / Ms. Serena Zhang / Ms. Cita Zhang / Ms. Willa Xue
Email: sinomab@financialpr.hk
Tel: (852) 2610 0846
Fax: (852) 2610 0842


Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Neurimmune: Promising Phase 1 Results for Antibody NI006 in ATTR Cardiomyopathy Published in the New England Journal of Medicine

ZURICH, SWITZERLAND, May 22, 2023 – (ACN Newswire) – Neurimmune announced today that primary results of its Phase 1 proof-of-concept study of NI006, a recombinant human antibody to deplete amyloid deposits in ATTR cardiomyopathy, have been presented in Prague at Heart Failure 2023, a scientific congress of the European Society of Cardiology (ESC), and published in The New England Journal of Medicine (DOI: 10.1056/NEJMoa2303765).

Amyloid transthyretin cardiomyopathy (ATTR-CM) is an underdiagnosed, systemic condition that leads to progressive heart failure and high rate of fatality within four years from diagnosis.1,2 Progressive ATTR amyloid depositions characterize the disease, causing heart failure and death. Despite recent advances and approved therapies, there remains significant unmet medical need in treating moderate to severe ATTR-CM, and amyloid depletion may constitute an important new mechanism to achieve further effectiveness.

NI006 has been designed to target the pathology of ATTR-CM by enabling depletion of amyloid fibrils in the heart. This Phase 1 study investigated safety, tolerability, pharmacology, and efficacy at 12 months of NI006 treatment in ascending doses.

Results indicate that the safety profile of NI006 is favorable up to the highest dose tested. No apparent dose-limiting toxic effects or drug-related serious adverse reactions were observed. The pharmacokinetic profile was consistent with that of an IgG antibody, and no antidrug antibodies were detected. At doses of at least 10 mg per kilogram, cardiac amyloid deposition (detected by either scintigraphy or cardiac magnetic resonance imaging) was substantially reduced over a period of 12 months. Reductions were also seen in levels of biomarkers measuring cardiac stress and cardiomyocyte death, N-terminal pro-B-type natriuretic peptide and troponin T.

"The depletion of the cardiac ATTR deposits is a rational therapeutic target to revert disease pathology and restore organ function", said Dr. Pablo Garcia-Pavia from the Hospital Universitario Puerta de Hierro and CNIC in Madrid, Spain, and principal investigator of the study. "The results of this study are very promising and show initial evidence that NI006 acts as a depleter of cardiac amyloid load with potential to improve cardiac structure, function and outcomes in ATTR cardiomyopathy."

"ATTR cardiomyopathy is a rare but serious condition that is progressive, systemic and potentially fatal," said Gianluca Pirozzi, SVP, Head of Development, Regulatory and Safety, Alexion. "These early results are encouraging, and we look forward to continuing to evaluate NI006 as a potential therapeutic option to address the high unmet medical need."

"We thank all patients, their families and investigators, study staff and collaborators for the participation in the NI006 first-in-human study," said Prof. Christoph Hock, Chief Medical Officer of Neurimmune. "The NI006 results warrant further development of this drug candidate with the potential of reverting disease progression in ATTR amyloidosis."

In 2022, Neurimmune entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca's Rare Disease group, for NI006. Neurimmune will continue to be responsible for completion of the current Phase 1 clinical trial on behalf of Alexion, and Alexion will pay certain trial costs. Following the Phase 1 trial, Alexion will be responsible for further clinical development, manufacturing, and commercialization.

1. Lauppe RE, et al. Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden. Open Heart. 2021 Oct;8(2):e001755. doi: 10.1136/openhrt-2021-001755.

2. Gonzalez-Duarte A, et al. Impact of non-cardiac clinicopathologic characteristics on survival in transthyretin amyloid polyneuropathy. Neurol Ther. 2020;9(1):135-149. doi:10.1007/s40120-020-00183-7.

NI006 Published Article in The New England Journal of Medicine:

Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid

Pablo Garcia-Pavia, MD PhD1; Fabian aus dem Siepen, MD2; Erwan Donal, MD PhD3; Olivier Lairez, MD4; Peter van der Meer, MD PhD5; Arnt V. Kristen, MD6; Michele F. Mercuri, MD PhD7; Aubin Michalon, PhD8; Robert J. A. Frost, MD PhD8; Jan Grimm, PhD8; Roger M. Nitsch, MD8,9; Christoph Hock, MD8,9; Peter C. Kahr, MD8,10; Thibaud Damy, MD PhD11.

N Engl J Med 2023; DOI: 10.1056/NEJMoa2303765

The authors' affiliations are as follows: 1) Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV, Madrid, Spain, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain, Universidad Francisco de Vitoria (UFV), Pozuelo de Alarcon, Spain 2) University Hospital Heidelberg, Department of Cardiology, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany 3) Department of Cardiology, University of Rennes, CHU Rennes, INSERM, LTSI – UMR 1099, Rennes, France 4) CHU de Toulouse – Hopital Rangueil, Service de Cardiologie, 1 Avenue du Pr. Jean Poulhes, 31059 Toulouse, France 5) Department of Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlandsn 6) Cardiovascular Center Darmstadt, Dieburger Strabe 31c, 64287 Darmstadt, Germany 7) Alexion/AstraZeneca Rare Disease, 121 Seaport Blvd, Boston, MA 02210, USA 8) Neurimmune AG, Wagistrasse 18, 8952 Schlieren, Switzerland 9) Institute for Regenerative Medicine, University of Zurich, Wagistrasse 13, 8952 Schlieren, Switzerland 10) Center for Molecular Cardiology, University of Zurich, Wagistrasse 13, 8952 Schlieren, Switzerland 11) Cardiology Department and French National Reference Centre for Cardiac Amyloidosis, at Hopitaux Universitaires Henri Mondor, AP-HP, and IMRB, INSERM, Universite Paris Est Creteil, 94010 Creteil, France.

www.neurimmune.com

Contact Information
Martin Meier-Pfister
Neurimmune Media Team
media@neurimmune.com

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

SinoMab Annouces IND Application of SM17 for the Treatment of Asthma was Accepted by NMPA CDE

HONG KONG, May 22, 2023 – (ACN Newswire) – A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases – SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company"), is pleased to announce that an Investigational New Drug ("IND") application for SM17 (a humanised anti-IL-17RB monoclonal antibody for injection) for the treatment of Asthma has been filed with and accepted by the Center for Drug Evaluation ("CDE") of the National Medical Products Administration of China ("NMPA") on 19 May. The present IND submission, once granted, will enable the Company to conduct comprehensive clinical development program in China which leads to indication for treatment of asthma.

SM17 is a humanized, IgG4-k monoclonal antibody targeting IL-17RB, which is a global first-in-class monoclonal antibody drug targeting IL17BR with the potential for treating asthma, atopic dermatitis, idiopathic pulmonary fibrosis and other immunological disorders. This IND application is mainly for the treatment of asthma, and upon approval of the present IND, the Company plans to initiate a Phase I clinical study in China to bridge between Chinese(Asian) and American(Caucasian/Black) populations, as well as to investigate the safety profile of SM17 in Chinese population.

As early as March 2022, SM17's IND Application for the treatment of asthma was approved by the U.S. Food and Drug Administration ("FDA"), and the first healthy subject had been successfully dosed in a Phase I clinical First-in-Human(FIH) clinical trial in June 2022. As of today, none of the subjects reported a serious adverse event. We are in full steam ahead to accelerate the progress of our clinical study. According to our current progress, we expect the Phase I clinical study can be completed by the end of this year, six months ahead of the original anticipated completion date.

SM17 could suppress Th2 immune responses by binding to IL-17RB on Type 2 Innate Lymphoid cells (ILC2s), blocking a cascade of responses induced by interleukin-25 (IL-25). IL-25 is a critical cytokine classified as "alarmin", which has shown to be implicated in the pathogenesis of airway viral responses and allergic disease, such as asthma. Patients with severe, uncontrolled asthma are at a risk of recurrent asthma exacerbations and hospitalizations, and uncontrolled severe asthma is associated with increased mortality/morbidity, diminished quality of life and increased health expenditures.

As one of the global pandemic, asthma has huge urgent and unmet medical needs, and the pharmaceutical market has a broad space. According to the Frost & Sullivan Report, the number of asthma patients worldwide is gradually increasing and expected to reach 800 million in 2024 and further increase to approximately 860 million in 2030. The number of asthma patients in China grew faster than the global growth rate and is expected to reach 70.4 million in 2024 and further increase to 78.1 million in 2030. In terms of market size, the global asthma product market is expected to reach US $38.5 billion in 2024 and US $50 billion by 2030. The asthma product market in China is expected to reach US $5.6 billion by 2024 and US $9.7 billion by 2030, of which the market size of moderate-to-severe asthma applicable for biologics will reach US $6.6 billion. Current approved therapies for severe asthma, including biologics, can reduce asthma annual exacerbations to a certain extent. However, there is still an unmet medical need for additional effective therapies, particularly for patients who do not respond to current treatments. The Company expected that targeting upstream mediators of the Th2 inflammatory cascade, such as IL-17RB, will have a broad effect on airway inflammation and improve disease conditions. The Company believes SM17 may have great potential to satisfy unmet medical needs in asthma treatment.

Dr. Shui On LEUNG, Executive Director, Chairman and Chief Executive Officer of SinoMab said that, "The number of asthma patients worldwide has increased year by year, and the existing therapies have not fully met the medical needs, and there is still a huge gap in effective treatment of severe asthma. As the world's first humanized IgG4-k monoclonal antibody targeting IL-17RB, SM17 has made satisfactory progress in clinical research under the active promotion of the Company. The acceptance of IND Application for SM17 not only accelerated the Company's clinical development project for the treatment of asthma indications in China, but also demonstrated the high efficiency of our new drug development. The Company is confident in the prospects of clinical trial and commercial development of the new drug of SM17, and will continue to explore its safety and efficacy. It is expected that this new treatment option will benefit more Chinese patients in the future and bring a promising treatment for severe asthma patients. The Company will adhere to independent innovation, continue to promote the investigatory of new drugs, expand the population of indications, spare no effort to provide more effective treatment options for Chinese and global patients, aiming to become a global leader in innovative therapies for immunological diseases."

About SinoMab BioScience Limited
SinoMab BioScience Limited is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The R&D headquarters is located in Hong Kong and the production base is located in mainland China. The Company's flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA) and has completed the Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), Alzheimer's disease, systemic lupus erythematosus (SLE), pemphigus (PV), multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), non-Hodgkin's lymphoma (NHL), asthma, and other diseases with major unmet clinical needs.

This press release is issued by Financial PR (HK) Limited on behalf of SinoMab BioScience Limited. For further information, please contact:

Financial PR (HK) Limited
Contact: Ms. Chloe Chiu / Ms. Serena Zhang / Ms. Cita Zhang / Ms. Willa Xue
Email: sinomab@financialpr.hk
Tel: (852) 2610 0846
Fax: (852) 2610 0842

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Fertilix Proven Effective in Blocking Damage From Low-Dose Exposure to Chemicals Commonly Found in Plastic Consumer Products

CLERMONT-FERRAND, FRANCE, May 19, 2023 – (ACN Newswire) – According to a recent study by Universite Clermont Auvergne researchers, exposure to chemical additives and building blocks commonly used in everyday plastic products, even in low doses, can cause significant damage to the genetic material carried by sperm cells.
Fertilix(R) logo


The study, led by Professor Joel Drevet, examined two common chemicals widely used in the plastic industry: dibutyl phthalate and bisphenol AF. These chemicals have long been linked to lowering male fertility, but the novelty of this study was in evaluating doses that were previously considered safe or inconsequential for consumers. While researchers found no appreciable effect on general semen parameters typically examined in fertility clinics such as sperm counts and motility, significant oxidation and decompaction of DNA structure in sperm cells were observed. This is concerning because damage to paternal genetic material can expose the female partner to higher risk of pregnancy loss and potentially impact the health of the offspring. Interestingly, the study also showed that co-administration with micronutrient supplement Fertilix(R) significantly blocked the damaging effects of these chemicals on sperm DNA.

Given that microplastics are found everywhere in our surroundings, these findings underscore the importance of greater public awareness and the urgency for the plastic industry to replace such substances with biodegradable or natural alternatives. Furthermore, fertility experts counseling couples ahead of natural or assisted conception should advocate for preconceptual supplementation and possible lifestyle modifications that may mitigate the impact of environmental pollutants.

This study is now available with open-access in Antioxidants, a premier journal in antioxidant research, and can be downloaded here. https://www.mdpi.com/2076-3921/12/5/1046 CellOxess Biotechnology, the designer and manufacturer of Fertilix(R) formulations, will present the full results of this study at the European Society of Human Reproduction and Embryology (ESHRE) annual meeting this June in Copenhagen, Denmark.

Contact Information
Frances Gallagher, MPH
Marketing & Communications Coordinator
contact@celloxess.com

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Healthcare Week boon for medical industry

HONG KONG, May 18, 2023 – (ACN Newswire) – Global healthcare sector leaders streamed into Hong Kong for the second International Healthcare Week, organised by the Hong Kong Trade Development Council (HKTDC). As the flagship Healthcare Week events, the third Asia Summit on Global Health (ASGH) and the 14th Hong Kong International Medical and Healthcare Fair (Medical Fair) featured fruitful discussions on a wide range of topics including the Guangdong-Hong Kong-Macao Greater Bay Area as an innovation powerhouse, complemented by exchanges on Chinese-Western medicine, aging and women innovators. This flagship event has confirmed Hong Kong's status as an international R&D and business healthcare platform, where university research projects have been linked with potential investors and innovative medical devices promoted to international markets.
The third Asia Summit on Global Health (ASGH) attracted over 2,500 participants from 40 countries
and regions

Connected through Deal-making in last Asia Summit on Global Health, representatives from Centre
for Eye and Vision Research Limited, a local university research centre, and Cloudbreak Pharma
Incorporated signed a MOU on ocular science research on the first day of the Summit, witnessed
by HKTDC Deputy Executive Director Dr Patrick Lau (2nd from left, back row)

HKTDC Hong Kong International Medical and Healthcare Fair features the latest medical and
healthcare products and technologies


The ASGH attracted over 2,500 participants from 40 countries and regions. The Medical Fair welcomed over 10,000 visitors from 56 countries and regions. More than 300 one-on-one deal-making sessions and over 600 business-matching meetings were also arranged to help participants seize business opportunities.

Dr Peter K N Lam, Chairman of the HKTDC, said: "Drawing on its strengths in scientific research, a world-class medical system, a highly skilled workforce, strong financing and fundraising capabilities and advanced logistics and transportation infrastructure, and backed by the huge market of the Greater Bay Area, Hong Kong is the preferred hub and perfect springboard into Asia for the growing healthcare market.

"The strong support from the healthcare industry for the Healthcare Week is overwhelming. It has created synergies for medical and healthcare industry professionals and unleashed Hong Kong's strengths in upstream and downstream healthcare industries, Hong Kong is ready to play a bigger role in the medical and healthcare fields in the region," Dr Lam added.

ASGH: thematic sessions examine hot topics

ASGH, co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the HKTDC, continued to bring together healthcare leaders, innovators and investors. The first-day Plenary Session: Reimagining the Future of Healthcare invited Sir Jonathan Symonds, CBE, Chair, GSK as one of the speakers. He said: "When COVID struck, the world didn't collaborate in the way that it should have. There will be another COVID. We cannot operate in the same way as we did. We must tackle global problems globally." Another speaker, Mr Tatsuo Yasunaga, Representative Director, Chair of the Board of Directors, Mitsui & Co., Ltd, noted: "In implementing value-based healthcare, we try to achieve both clinical outcome improvement and cost savings. We expect to achieve the first goal through new drug and medical device developments and health risk management. We are also moving towards personalised healthcare to bridge the gap between medical care and prevention."

The Unleashing Opportunities in Integrative Chinese-Western Medicine session today examined research, treatment and medicine developments that transformed markets in Asia and abroad. The session showcased the potential for complementary, integrative healthcare and highlighted the business opportunities that collaboration between Chinese and Western medicine presented.

Mr Abraham Chan, Founder, Chairman, CEO and Executive Director at PuraPharm said modernising Chinese medicine included standardising products by creating standardised granules from herbs. Computer programmes let practitioners diagnose conditions and dispense treatments. Big data collected by practitioners helped improve products and perform drug discovery.

Noting Hong Kong's high life expectancy and increase in the elderly population, panelists at the Ageing Well: Breakthroughs and Investment Landscape in Longevity session said this presented both challenges and opportunities, such as drug discovery, research financing and monitoring gadgets.

Dr Donald Li, Chairman of the Elderly Commission, said higher demand for a wide range of healthcare products and services generated opportunities. This was especially true of monitoring devices allowing the elderly to live at home safely.

Medical Fair: A proven platform reaching out to global buyers

The Medical Fair, organised by the HKTDC and co-organised by the Hong Kong Medical and Healthcare Device Industries Association (HKMHDIA) ran under the HKTDC's EXHIBITION+ hybrid model. The physical fair at the Hong Kong Convention and Exhibition Centre (HKCEC) successfully closed today, while exhibitors and buyers from around the world can continue conducting business online via the Click2Match smart business-matching platform until 25 May.

University projects showcased

In recent years, the Hong Kong SAR Government has actively promoted collaboration between the government, industry, academia and researchers by bringing together enterprises, universities and research institutes to cooperate and promote technological innovation.

At ASGH, the hybrid InnoHealth Showcase and exhibition zone featured projects and solutions from more than 140 healthcare-related innovative technology enterprises, from which 50 of the enterprises and projects are presented by five local major universities, namely CUHK, HKBU, HKU, HKUST and PolyU. The Co-founder, Director & Chief Scientific Advisor of exhibitor Gut Rhythm R&D (Hong Kong) Limited Prof John Anthony Rudd said: "The event was highly successful for us. We gained a lot of exposure and were able to attract several potential investors. We also learned a lot and are very confident we could move forward."

Innovation and Technology Commission (ITC) and Cyberport joined ASGH as Health Innovation Partners from which ITC showcased 16 health-related InnoHK R&D centres to demonstrate Hong Kong's strength as a global innovation powerhouse.

Numerous companies in the healthcare industry as well as six local universities and various enterprises supported by the universities, which are commercialising their research and development accomplishments, joined the Medical Fair to showcase cutting-edge medical products and technologies. Among the university-affiliated companies are Sramek Insight Limited, Herbap Biotech, Agilis Robotics, Metasurgical Technology, Cellomics International and Greater Bay Biotechnology.

This year's fair, the largest in its history, assembled more than 300 exhibitors to feature the latest medical technologies and equipment, healthcare products and solutions and related services, drawing many buyers and industry professionals to source both onsite and online.

"I am glad that I met nearly 100 representatives from various medical organisations, our main target customers. I estimate that this fair will make over 60% of our yearly sales," said Mr King-Wah Tai, a sales representative for medical facility manufacturer Janley Limited (HK). The company has participated in the Medical Fair since 2014 and has benefited greatly from this year's fair. "Taking this chance to interact with people from the sector, understand what they need and how they think is very important to our business. The fair is not just for generating sales but also the perfect place to gain insight," Mr Tai added.

Mr Valentin Cipian Pantea, Manager of Neomed S.R.L. from Romania, visited the Medical Fair to look for new medical-uniform manufacturers. "I plan to order about US$200,000 worth of products and hope to build a long-term relationship with them. Besides, using the Click2Match platform, I made a valuable business connection with a manufacturer from Mainland China. The platform is very helpful in getting to know people entirely out of our usual circle."

A number of content-rich events, including the highly anticipated HKMHDIA Medical Fair Forum, were held during the Medical Fair with keen participation from industry professionals. Those who missed the seminars can watch replay videos on the fair's website at https://bit.ly/3DNBBXy.

Websites
– International Healthcare Week: https://internationalhealthcareweek.hktdc.com/en
– Asia Summit On Global Health: https://www.asiasummitglobalhealth.com/conference/asgh/en
– Programme: https://www.asiasummitglobalhealth.com/conference/asgh/en/programme
– Speakers: https://www.asiasummitglobalhealth.com/conference/asgh/en/speaker
– Hong Kong International Medical and Healthcare Fair: https://www.hktdc.com/event/hkmedicalfair/en
– Interesting product list and Activity schedule: https://bit.ly/3V9mv6S
– Media Room: http://mediaroom.hktdc.com
– Photo download: https://bit.ly/3pTmGI0

About HKTDC

The Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Follow us on Twitter @hktdc and LinkedIn

Media enquiries

For enquiries please contact:

Asia Summit on Global Health
Yuan Tung Financial Relations:
Anson Wong, Tel: +852 3428 3413, Email: awong@yuantung.com.hk
Agnes Yiu, Tel: +852 3428 5690, Email: ayiu@yuantung.com.hk
Hing-Fung Wong, Tel: +852 3428 3122, Email: hfwong@yuantung.com.hk

HKTDC's Communications & Public Affairs Department:
Janet Chan, Tel: +852 2584 4369, Email: janet.ch.chan@hktdc.org
Agnes Wat, Tel: +852 2584 4554, Email: agnes.ky.wat@hktdc.org

Hong Kong International Medical and Healthcare Fair
HKTDC's Communications & Public Affairs Department:
Frankie Leung, Tel: +852 2584 4298, Email: frankie.cy.leung@hktdc.org

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Asia Summit on Global Health gathers 90+ global elites

HONG KONG, May 17, 2023 – (ACN Newswire) – The second International Healthcare Week (IHW), organised by the Hong Kong Trade Development Council (HKTDC), kicked off yesterday, highlighting Hong Kong's strategic role as an innovation and investment hub for the healthcare industry in Asia and its position as a research and business platform for global healthcare development. A flagship event of IHW, the third Asia Summit on Global Health (ASGH) opened today (17 May), while another highlighted event, the 14th edition of the HKTDC Hong Kong International Medical and Healthcare Fair, began yesterday.
The third Asia Summit on Global Health, co-organised by the HKSAR Government and the HKTDC,
began today under the theme "Reimagining the Future of Healthcare"

Dr Peter K N Lam, HKTDC Chairman, gives his welcome remarks

The Hong Kong International Medical and Healthcare Fair features several exhibition zones such as
Biotechnology, Hospital Equipment, Rehabilitation and Elderly Care Products, Health and Personal Care,
and Medical and Healthcare Supplies.


The two-day ASGH, co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the HKTDC, takes place in person at the Hong Kong Convention and Exhibition Centre (HKCEC) today, with tomorrow's second day being entirely virtual. This year's summit runs under the theme "Reimagining the Future of Healthcare" and features more than 90 speakers from 20 countries and regions, including healthcare officials and organisations, international science and medical experts, university academics and researchers, investors, business leaders and financial specialists. They are discussing the latest developments in public health, medical technology and healthcare investment to comprehensively explore the future of the healthcare ecosystem and the opportunities it presents.

Mr John Lee, Chief Executive of the HKSAR, delivered the ASGH's opening remarks this morning, with Dr Peter K N Lam, HKTDC Chairman, giving the welcome address. Ms Yu Yanhong, Member of the Leading Party Members' Group of the National Health Commission of the People's Republic of China and Secretary of the Leading Party Members' Group of the National Administration of Traditional Chinese Medicine, delivered special remarks. Dr Peter K N Lam said: "As we find ourselves on the road to recovery, it is an opportune time to look back at the last few years and outline our vision for the global healthcare industry in the years ahead. I am sure we can all agree that we must make the industry more resilient and sustainable for future generations to withstand any health crises. And Hong Kong is the ideal location for the healthcare community to reimagine a bright future for the industry."

In his opening remarks, Mr John Lee said: "Less than two weeks ago, the World Health Organization declared an end to the classification of COVID-19 as a 'public health emergency of international concern'. Here in Hong Kong, and throughout the world, life, and business, is returning to normal. The Hong Kong SAR Government, working together with our R&D and I&T institutions, businesses and professionals, is committed to building a more resilient and sustainable global health system. This Summit, I'm confident, will move us all along in the right direction, a shared determination to build the highest, most inclusive, standard of health and prosperity we can offer our economies, our societies and our communities."

In her special remarks to the audience, Ms Yu Yanhong said: "The 20th National Party Congress emphasised the importance of fostering a 'Healthy China' and giving strategic priority to the protection of the population's health. We hope to promote mutual development by collaborating with Asia's medical and health professionals. This includes enhancing collaboration in medical technology innovation and clinical applications, combining the strengths of biomedical research and industry, complementing each other's resources for mutual benefit, and focusing on global, open development to create a global community of health for all."

Also addressing the summit this morning was Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), who said: "While COVID-19 may no longer be a global health emergency, the threat of another more disruptive pathogen remains. To keep the world safer against emergencies of all kinds, the WHO has proposed a framework for stronger governance, financing, systems and tools, and is supporting the international pandemic accord now being negotiated by countries. It is time to end the cycle of panic and neglect in health, and work together to build a new future that's equitable, inclusive and coherent."

Charting healthcare progress in the post-pandemic era to explore opportunities

In the post-pandemic world, the top priority is to reimagine the future of healthcare, with key business leaders, pharmaceutical giants, investors and global health pioneers all needing to contribute to improvements in patient care. This morning's "Plenary Session: Reimagining the Future of Healthcare", moderated by Mr Victor Chu, Chairman & CEO of First Eastern Investment Group, invited Sir Douglas Flint, Chairman of abrdn plc and Chairman of the IP Group, as guest speaker for the first part of the session, the Fireside Chat. Sir Douglas said: "The pandemic has demonstrated the importance of multidisciplinary, multi-country collaboration in addressing global health challenges. With its young population, rising research and development and exceptional scientific talent pool, Asia will play a leading role in global healthcare development going forward. Hong Kong's efforts to attract talent and investment to the region and to build regulatory frameworks that bridge Asian and Western scientific research and development are also vital."

This was followed by "Plenary Talk: The Future of Healthcare as Enabled by Technology and AI", with Dr Gerald L Chan, co-founder of the Morningside Group, invited to explain how AI can help facilitate future developments in the healthcare industry. Dr Chan said: "The explosive rise in the demand for healthcare as well as healthcare costs, combined with an increase in life expectancy, is putting a strain on global healthcare systems. In the face of this demand-supply imbalance, the only way to bridge the gap is to use scalable technology, such as data and artificial intelligence. This will allow us to augment the system so that, despite limited resources, we can care for more patients and meet the seemingly insatiable demand for healthcare."

Tomorrow (18 May) will see a diverse array of online sessions covering topics such as AI, biotechnology, the new focus on Asian healthcare, climate change and health, the future direction of healthcare services, women innovators and investors in healthcare, breakthroughs and the investment landscape in longevity, opportunities in integrative Chinese-Western medicine, and mental health and holistic wellness. Sharing their insights will be scholars, medical specialists, research and innovation leaders, and financial elites from Asia and around the world.

Holistic platform to connect investment projects and boost collaboration

This year's summit features ASGH Deal-Making from 17 to 23 May, connecting project owners with potential investors and business partners worldwide and covering projects such as pharmaceuticals, medical devices and diagnostics, AI and digital health, community health and wellness. The InnoHealth Showcase and exhibition area, running both online and offline, features projects and services from more than 140 innovative technology companies related to the healthcare industry, allowing them to connect with investors from around the world. Among them, 50 innovative start-ups and projects are led by five local universities, including the University of Hong Kong, the Chinese University of Hong Kong, the Hong Kong University of Science and Technology, Hong Kong Baptist University and the Hong Kong Polytechnic University, many of which won multiple awards at this year's Geneva International Exhibition of Inventions. The Innovation and Technology Commission (ITC) and Cyberport continue to be Health Innovation Partners of the summit and are showcasing their solutions at the event. ITC has gathered 16 research centres under the InnoHK initiative to demonstrate Hong Kong's strength as a global research hub. And today's Business of Healthcare Advisory Zone targets biotechnology and healthcare start-ups with a range of consulting services offered by investors and industry experts.

Cutting-edge medical devices and technological solutions at Medical Fair

The Hong Kong International Medical and Healthcare Fair, organised by the HKTDC and co-organised by the Hong Kong Medical and Healthcare Device Industries Association (HKMHDIA), showcases cutting-edge medical devices and technological solutions under the theme "Unleash the Power of Smart Health". The fair has attracted more than 300 exhibitors from local and international markets, including Canada, Mainland China, Japan, Taiwan and the United States. This year's fair is the biggest in the event's history, with many exhibitors investing more resources than before the pandemic.

This year's themed zones at the fair include Biotechnology, Hospital Equipment, Rehabilitation and Elderly Care, World of Health and Wellness, and Medical Supplies and Disposables. There are also exclusive exhibition areas for the HKMHDIA, Hong Kong China Federation of Bodybuilding & Fitness, and Hong Kong Science and Technology Parks (HKSTP). The zones showcase a range of cutting-edge medical technologies and instruments, healthcare products and related services.

Among the exhibitors, one company is showcasing a "telehealth management platform" that enables medical staff to monitor patients' blood pressure, blood oxygen saturation and body temperature in real-time using Bluetooth medical devices (Booth: 3E-E27). Another exhibitor is introducing an "electronic stethoscope" that allows healthcare professionals to conduct remote auscultation (Booth: 3D-E01).

The Medical Fair has invited six local universities, including the University of Hong Kong, the Chinese University of Hong Kong, the Hong Kong University of Science and Technology, City University of Hong Kong, Hong Kong Baptist University and Lingnan University, to showcase their R&D achievements in the medical and healthcare field, while the exhibition area set up by the HKSTP allows 30 companies, including start-ups they have incubated, to showcase their innovative achievements. Among them, a company is demonstrating a nucleic acid drug delivery system using "electroporation" which utilises brief electric pulses to enhance drug penetration across the cell membrane and help induce a more potent immune response (Booth: 3E-E28).

Held yesterday, the HKMHDIA Medical Fair Forum 2023 was a major highlight of this year's fair. Organised by the HKMHDIA with the HKTDC as a strategic partner, the event featured industry experts who discussed the opportunities and prerequisites for establishing medical technology companies in Hong Kong and mainland cities in the Guangdong-Hong Kong-Macao Greater Bay Area. Today, "The Rise of Innovative MedTech in Hong Kong" forum, organised by HKSTP, introduced new solutions from medical technology companies including a next-generation bone density testing system and an ultrasound system for monitoring liver disease.

This year's Medical Fair continues to use the "EXHIBITION+" model, with the physical exhibition taking place at the Hong Kong Convention and Exhibition Centre from 16 to 18 May. Global exhibitors, industry professionals and buyers can also conduct business negotiations through the "Click2Match" online smart business matching platform until 25 May.

Websites
– International Healthcare Week: https://internationalhealthcareweek.hktdc.com/en
– Asia Summit On Global Health: https://www.asiasummitglobalhealth.com/conference/asgh/en
– Programme: https://www.asiasummitglobalhealth.com/conference/asgh/en/programme
– Speakers: https://www.asiasummitglobalhealth.com/conference/asgh/en/speaker
– Hong Kong International Medical and Healthcare Fair: https://www.hktdc.com/event/hkmedicalfair/en
– Interesting product list and activity schedule: https://bit.ly/3V9mv6S
– Media Room: http://mediaroom.hktdc.com
– Photo download: https://bit.ly/3OziSpJ

About HKTDC

The Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Follow us on Twitter @hktdc and LinkedIn

Media enquiries

For enquiries please contact:

Asia Summit on Global Health
Yuan Tung Financial Relations:
Anson Wong, Tel: +852 3428 3413, Email: awong@yuantung.com.hk
Agnes Yiu, Tel: +852 3428 5690, Email: ayiu@yuantung.com.hk
Hing-Fung Wong, Tel: +852 3428 3122, Email: hfwong@yuantung.com.hk

HKTDC's Communications & Public Affairs Department:
Janet Chan, Tel: +852 2584 4369, Email: janet.ch.chan@hktdc.org
Agnes Wat, Tel: +852 2584 4554, Email: agnes.ky.wat@hktdc.org

Hong Kong International Medical and Healthcare Fair
HKTDC's Communications & Public Affairs Department:
Frankie Leung, Tel: +852 2584 4298, Email: frankie.cy.leung@hktdc.org

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Owkin Receives European Medicines Agency Letter of Support for Innovative AI-Driven Approach to Oncology Trial Analysis

PARIS, FRANCE, May 17, 2023 – (ACN Newswire) – AI Biotech Owkin, a leading provider of AI-powered solutions for drug discovery and clinical development, has received a letter of support from the European Medicines Agency (EMA) regarding their proposed statistical adjustment on deep learning prognosis covariates obtained from histological slides. The proposed method uses the predictions of two deep-learning models, MesoNet and HCCnet, as prognostic biomarkers for the adjustment of efficacy analysis on the overall survival of life-prolonging drugs in randomized phase 2 and phase 3 clinical trials.
EMA endorsement of AI optimization of clinical trials


MesoNet and HCCnet are proprietary deep-learning models trained using digitized pathology imaging from mesothelioma and hepatocellular carcinoma (HCC) patients to predict overall survival. The training is performed with an algorithm that uses pre-trained models to extract information from images and focuses on small regions of the biopsy that are most relevant to prediction. The models brought a significant improvement in prognostic performance for overall survival when added to currently used stratification factors.

The proposed context of use is to apply the deep-learning models' predictions as prognostic biomarkers for the adjustment of efficacy analysis on overall survival of life-prolonging drugs in randomized phase 2/3 clinical trials. The MesoNet predictions will be used to adjust efficacy analysis on the overall survival of life-prolonging drugs in first-line malignant pleural mesothelioma patients in randomized phase 2/3 clinical trials. The HCCnet predictions will be used to adjust efficacy analysis on the overall survival of life-prolonging drugs in the adjuvant setting for resected hepatocellular carcinoma patients in randomized phase 2/3 clinical trials.

The EMA recognizes that the proposed AI models' main proposed strength is the gain in prognostic performance compared to current practice's covariate adjustment in clinical trial settings. The models' interpretability features allow researchers to understand the salient features that informed the model's prediction and avoid the drawbacks of black box AI models. However, the evidence base for the AI model approach as new technology is limited compared to traditional approaches. Therefore, Owkin is encouraged to use their approach in future trials and do additional prospective validation.

Felix Balazard, Director of Optimized Development at Owkin said: "This EMA letter of support offers a clear regulatory path for integrating AI models based on histopathology into the analysis of randomized clinical trials. Owkin is bringing AI to the regulatory setting."

Covariate adjustment has been endorsed by regulatory agencies like the EMA and FDA, and Owkin believes that its data-driven approach to this statistical method can significantly improve the success rates of trials, including the ongoing mesothelioma and HCC trials. With Owkin's Federated Research Network, it can develop on-demand prognostic scores for other indications, which can further reduce clinical trial failure rates.

Contact Information
Antonia Trower
VP of Marketing
antonia.trower@owkin.com
+447539359014

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat

KIEL, GERMANY, May 17, 2023 – (ACN Newswire) – tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
tiakis Biotech AG and Northway Biotech collaboration – tiakis Biotech AG and Northway Biotech:
Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat


"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.

The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.

Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."

Andre Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."

By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.

About Tiprelestat

tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.

About tiakis Biotech AG

tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).

About Northway Biotech

Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.

Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

ZeptoMetrix Launches PROtrol: Quality Control Material for the Lateral Flow Immunoassay Market

BUFFALO, NY, May 16, 2023 – (ACN Newswire) – ZeptoMetrix(R) is excited to introduce PROtrol(TM), a new line of products designed for antigen-based diagnostic methods. These third-party materials mimic a true clinical specimen and can be used to evaluate and monitor the performance of antigen-based assays, including lateral flow immunoassays for infectious diseases.

PROtrol is the only whole organism reference material to provide complete testing data. Each lot of product is supplied with the protein concentration and TCID50 value, which minimizes qualification testing. PROtrol provides better reproducibility, which optimizes the use of financial spending and processing time through the decreased need for repeat testing.

"The rapid expansion in development of antigen-based assays has highlighted some quality challenges. Inactivated, whole organism controls designed specifically for antigen tests can equip manufacturers with the tools they need to better evaluate the performance of their assays, leading to higher quality tests on the market," said Dr. Karuna Sharma, Vice President & Chief Scientific Officer.

PROtrol SARS-Related Coronavirus 2 (SARS-CoV-2) Isolate: USA-WA1/2020* is the first member of this product line (PROSARS(COV2)-587). As we move beyond the COVID-19 pandemic, ZeptoMetrix will continue to grow the PROtrol product line, providing high-quality controls to assay manufacturers seeking to expand access to inexpensive and easy-to-use diagnostics.

"The launch and expansion of PROtrol enhances our position as the partner of choice for diagnostic test developers," said Evangeline Gonzalez, President of Antylia Diagnostics division. "As we work with our diagnostic partners, ZeptoMetrix is pleased with the role that PROtrol plays to give patients around the world more access to diagnostic testing."

More information on how to order the new PROtrol and additional ZeptoMetrix products can be found at: https://www.zeptometrix.com

About ZeptoMetrix(R)

ZeptoMetrix(R) is an established industry leader in the design, development, and delivery of innovative, quality solutions to the infectious disease diagnostics market. Our expertise and abilities in molecular diagnostics, including external quality controls, verification panels, proficiency panels, customized and OEM products/services have set the industry standard for performance and reliability and make ZeptoMetrix the preferred choice for independent third-party quality control materials.

Links:
* (PROSARS(COV2)-587): product page
https://www.zeptometrix.com/products/protrolt-sars-cov-2-isolate-usa-wa1-2020-1-ml

Contact Information
Andrew Zenger
Global Product Manager
andrew.zenger@antylia.com
(716) 715-7417

Related Files
PROSARS(COV2)-587 Product Insert.pdf https://cdn.newswire.com/files/x/f7/75/6f2724d112cd754a1e946ada2060.pdf
ZeptoMetrix Launches PROtrol.pdf https://cdn.newswire.com/files/x/94/c9/f6adf7dcd8a49a3ac3d828c851a5.pdf

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Malaysian Genomics Inks Agreement in Expansion to Bangladesh

PETALING JAYA, Malaysia, May 15, 2023 – (ACN Newswire) – Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, today announced a strategic cooperation agreement (SCA) with Toticell Limited for the distribution of the Group's products in Bangladesh.
Sasha Nordin, Chief Executive Officer of Malaysian Genomics

Azri Azerai, Executive Director of Malaysian Genomics


Toticell, which is based in Dhaka, Bangladesh, specialises in regenerative healthcare focusing on treatments for musculoskeletal conditions such as arthritis, sports-related injuries and tendinopathies.

Under the SCA, the parties agree to cooperate in the distribution of Malaysian Genomics' cosmeceutical products, genetic screening tests, CAR T-cell therapy services, and other areas of mutual commercial interests.

Mr. Sasha Nordin, CEO of Malaysian Genomics said, "Bangladesh represents a market with vast opportunities given its population of approximately 165 million people. The country's economy, which is the second-largest in South Asia, is growing rapidly it is identified by Goldman Sachs Inc. as one of the Next Eleven, along with the BRICS economies for potential. Malaysian Genomics is delighted to cooperate with Toticell to bring our products and services to Bangladesh."

Mr. Azri Azerai, Executive Director of Malaysian Genomics, said, "This collaboration with Toticell falls in line with Malaysian Genomics' strategic expansion plan which includes diversifying geographically and globally."

In April, MGRC announced that the Group has made progress in establishing partnerships following the signing of SCAs with several Dubai, United Arab Emirates ("UAE") parties, namely American Spine Center ("ASC"), a Dubai, UAE-based specialist in spinal injury and spine pathology; BALSAM Health Services ("Balsam"), a Dubai, UAE-based healthcare service provider; Wellness by Design FZ LLC ("Wellness by Design"), a Dubai, UAE-based nutrition, obesity and weight loss specialist, and Sharjah, UAE-based IAC International LLC ("IAC"), which is coordinating and developing the partnerships.

MGRC also recently appointed Mr. Aswath Ramakrishnan as its new Independent Non-Executive Director. He is an experienced practising lawyer involved in commercial litigation, shipping and maritime, defamation, corporate and insolvency litigation, asset and debt recovery, intellectual property litigation, arbitration, and cross-border dispute.

Malaysian Genomics Resource Centre Bhd: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com